2026-03-31 04:56:08
Latest Post
PNC Infratech Completes Sale of Equity Stake in PNC Challakere Karnataka Highways Private Limited
P N Gadgil Jewellers Ltd opens new store in Varanasi
Gujarat Inject Kerala Ltd receives order of Rs. 3.11 crores
Saatvik Solar Industries Pvt Ltd accepts order of Rs. 14 crores
Avenue Supermarts Ltd opens 5 new stores today
Stock Report
Dr Reddys enters the Dermatology topical steroid market, launches 'UltravexTM' - (Halobetasol)
Posted On : 2007-06-08 02:05:16( TIMEZONE : IST )
Dr Reddys Laboratories Ltd has announced that UltravexTM (Halobetasol) has been launched nationwide in June marking the entry of the Company's Dermatology in the topical steroid Rs 100 crore market. Halobetasol is a super - potent steroid and hence has a higher efficacy associated with the product. UltravexTM is currently available in 10 gm pack and is used in the treatment of Psoriasis and Chronic Dermatoses.
The topical steroid market is the second most prescribed category by dermatologists with nearly 2.5 crore units sold every year. With the launch of this product, the Company steps into a mass specialty area which has an higher incidence of prescription due to its indication (Psoriasis and Chronic Dermatoses).
The stock was trading at Rs.635, down by Rs.11.40 or 1.76%. The stock hit an intraday high of Rs.644 and low of Rs.627.30. The total traded quantity was 158893 compared to 2 week average of 103975.
